Importance: Although HIV preexposure prophylaxis (PrEP) implementation among persons who inject drugs has been inadequate, national HIV monitoring programs do not include data on PrEP, and specific trends in PrEP use are not well understood.
Objective: To estimate HIV PrEP uptake among commercially insured persons with opioid or stimulant use disorder by injection drug use (IDU) status.
Design, Setting, And Participants: This cross-sectional study used deidentified data from the MarketScan Commercial Claims and Encounters Database to identify a sample of 547 709 commercially insured persons without HIV but with opioid and/or stimulant use disorder, including 110 592 with evidence of IDU between January 1, 2010, and December 31, 2019. Data were analyzed from November 1, 2020, to July 1, 2021.
Exposures: Persons with opioid and/or stimulant use disorder and evidence of IDU were identified through claims data.
Main Outcomes And Measures: The outcome was receipt of tenofovir disoproxil fumarate and emtricitabine for PrEP as identified from filled pharmacy claims. Multivariable logistic regression was used to assess the association of demographic and clinical characteristics with receipt of PrEP.
Results: The study cohort included 211 609 (28.6%) females and 336 100 (61.4%) males with a combined mean (SD) age of 34.8 (13.1) years, including 110 592 individuals with evidence of IDU. During the study period, 508 (0.09%) persons with opioid and/or stimulant use disorder, including 170 (0.15%) with evidence of IDU, received PrEP. Receipt of PrEP increased from 0.001 to 0.243 per 100 person-years from 2010 through 2019 among the entire cohort and from 0.000 to 0.295 per 100 person-years among those with IDU. In multivariable analysis, PrEP use was more likely among males (adjusted odds ratio [aOR] 8.72; 95% CI, 6.39-11.89), persons with evidence of IDU (aOR, 1.47; 95% CI, 1.21-1.79), and persons with evidence of sexual risk indications for PrEP (aOR, 23.68; 95% CI, 19.57-28.66).
Conclusions And Relevance: In this cross-sectional study of commercially insured persons with opioid and/or stimulant use disorder, HIV PrEP delivery remained low, including among those with evidence of IDU. PrEP should be consistently offered alongside substance use disorder treatment and other harm reduction and HIV prevention services.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277489 | PMC |
| http://dx.doi.org/10.1001/jamanetworkopen.2022.21346 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Formative evaluation of the implementation of digital therapeutics for opioids and other substance use disorders in primary care (DIGITS trial).
Implement Res Pract
December 2024
Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Background: Substance use disorders (SUDs) result in individual and societal burden. However, most individuals with SUD receive no treatment. Implementing SUD interventions in primary care could address this population's treatment needs.
View Article and Find Full Text PDFArticle Synopsis
- Nigeria has one of the highest rates of drug use globally, particularly opioids, with a low uptake of medication-assisted treatment (MAT) despite existing guidelines.
- A study surveyed 329 substance use professionals (SUPs) in Nigeria to assess their knowledge and attitudes towards MAT for opioid dependence.
- Results indicated that while most SUPs supported the need for MAT, many lacked prior experience, training, and awareness of guidelines, highlighting a need for improved education and resource availability.
Background: Rates of drug use in Nigeria are one of the highest globally, with the use of opioids associated with increased morbidity and mortality more so with injecting drug users (IDU). MAT) can reduce the harmful effects of opioid use but usage in the country is low despite a country-specific guideline in place. A notable barrier to MAT uptake is professionals' knowledge and attitudes.
View Article and Find Full Text PDFPrescription Digital Therapeutics for Substance Use Disorder in Primary Care: Mixed Methods Evaluation of a Pilot Implementation Study.
JMIR Form Res
September 2024
Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States.
Background: Delivering prescription digital therapeutics (ie, evidence-based interventions designed to treat, manage, or prevent disorders via websites or smartphone apps) in primary care could increase patient access to substance use disorder (SUD) treatments. However, the optimal approach to implementing prescription digital therapeutics in primary care remains unknown.
Objective: This pilot study is a precursor to a larger trial designed to test whether implementation strategies (practice facilitation [PF] and health coaching [HC]) improve the delivery of prescription digital therapeutics for SUDs in primary care.
Understanding hepatitis C virus (HCV) health literacy and educational needs among people in prison to enhance HCV care in prisons.
Int J Drug Policy
August 2024
The Kirby Institute, University of New South Wales, Australia; Centre for Social Research in Health, University of New South Wales, Australia.
Background: Hepatitis C virus (HCV) is a significant concern within prison populations. Provision of HCV testing and treatment for people in prison is expanding and a key component of global elimination efforts. Despite growing service availability, several challenges remain in HCV testing and treatment engagement during incarceration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!